ERBB2 and breast carcinoma: In breast cancer, the combination of zilovertamab and paclitaxel has been demonstrated to be more effective than either of the treatments alone in vivo [18], and formed the preclinical evidence for combined treatment in the HER2-negative breast cancer clinical trial (NCT02776917).